PriceTargets.com logo

Immutep - IMMP Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.91 As of 02/6/2023 01:00 AM ET
▼ -0.06 (-3.05%)

This chart shows the closing price for IMMP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Immutep Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IMMP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IMMP

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Immutep in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.91.

This chart shows the closing price for IMMP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Immutep. This rating has held steady since November 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/16/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/14/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/12/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/13/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/11/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/9/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/8/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/7/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/2/2021Jefferies Financial GroupInitiated CoverageBuyMedium
8/3/2021LADENBURG THALM/SH SHInitiated CoverageBuy$8.30Medium
6/10/2021Alliance Global PartnersBoost TargetBuy$6.00 ➝ $9.00Low
1/26/2021Alliance Global PartnersBoost TargetBuy$5.00 ➝ $6.00Medium
12/14/2020Maxim Group$4.00 ➝ $8.00N/A
11/11/2020Maxim GroupBoost TargetPositive ➝ Buy$2.00 ➝ $4.00High
9/22/2020Alliance Global PartnersInitiated CoverageBuyLow
6/2/2020Maxim GroupReiterated RatingBuy$2.00Low
4/30/2020Maxim GroupInitiated CoverageBuy$2.00Low
9/24/2019Maxim GroupReiterated RatingBuy$4.00High
7/31/2019Maxim GroupSet TargetBuy$4.00N/A
5/1/2019Maxim GroupReiterated RatingBuy$7.00High
11/27/2018Maxim GroupSet TargetBuy$7.00Medium
11/12/2018Maxim GroupReiterated RatingBuy$7.00High
9/28/2018B. RileyInitiated CoverageBuy ➝ Buy$7.75High
5/25/2018Maxim GroupBoost TargetPositive ➝ Buy$5.00 ➝ $7.00Low
3/22/2018Maxim GroupInitiated CoverageBuy$5.00Low
3/15/2018Maxim GroupSet TargetBuy$5.00Low
2/15/2018Maxim GroupReiterated RatingBuy ➝ Buy$7.00 ➝ $5.00Medium
(Data available from 2/7/2018 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 3 very negative mentions
Mentions as of
7/12/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
8/11/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/10/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 4 very negative mentions
Mentions as of
10/10/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/9/2022
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/9/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/8/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/7/2023

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Immutep logo
Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alpha (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.
Read More

Today's Range

Now: $1.91
Low: $1.90
High: $1.99

50 Day Range

MA: $2.03
Low: $1.71
High: $2.53

52 Week Range

Now: $1.91
Low: $1.47
High: $3.45

Volume

41,587 shs

Average Volume

79,234 shs

Market Capitalization

$167.95 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.33

Frequently Asked Questions

What sell-side analysts currently cover shares of Immutep?

The following Wall Street sell-side analysts have issued stock ratings on Immutep in the last twelve months:
View the latest analyst ratings for IMMP.

What is the current price target for Immutep?

0 Wall Street analysts have set twelve-month price targets for Immutep in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Immutep in the next year.
View the latest price targets for IMMP.

What is the current consensus analyst rating for Immutep?

Immutep currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for IMMP.

What other companies compete with Immutep?

Other companies that are similar to Immutep include Shattuck Labs, CytomX Therapeutics, Ovid Therapeutics, Omeros and Xeris Biopharma. Learn More about companies similar to Immutep.

How do I contact Immutep's investor relations team?

Immutep's physical mailing address is LEVEL 12 95 PITT STREET, SYDNEY C3, 2000. The biotechnology company's listed phone number is (128) 315-7003 and its investor relations email address is [email protected] The official website for Immutep is www.immutep.com. Learn More about contacing Immutep investor relations.